Affitech A/S strengthens its IP portfolio on anti-VEGF antibody AT001/r84

14-Oct-2011 - Affitech A/S announced that the U.S. Patent and Trademark Office (USPTO) has granted Affitech U.S. patent (no. 8,034,905) covering the Company’s anti-VEGF antibody drug candidate AT001/r84. The newly granted US patent is the first patent grant Affitech has received for this compound in a major ...

Affitech A/S receives EUR 2.5 million license fee for development of new anti-VEGF antibody drug in Russia

20-Jun-2011 - Affitech A/S announced that IBC Generium has exercised the license to Affitech’s lead anti-VEGF antibody drug candidate AT001/r84. The license grant triggered a payment of Euro 2.5 million by IBC Generium to Affitech A/S and provides IBC Generium with the exclusive rights to develop and market ...

Affitech A/S signs research agreement with UT Southwestern to support further development of its lead antibody drug candidate AT001/r84

28-Apr-2011 - Affitech A/S announced that the Company has signed a sponsored research agreement with Dr. Rolf Brekken at the University of Texas Southwestern Medical Center, Dallas, USA to further understand the mechanism and potential differentiation of Affitech’s lead antibody drug candidate AT001/r84.The ...

Affitech's lead drug candidate AT001/r84 potent on tumours in mice studies with limited induction of side effects

10-Aug-2010 - Affitech A/S announced that the Company's lead drug candidate r84, which may have therapeutic application against certain cancers, shows potent activity on tumours and does not induce significant side effects in mice. This is the conclusion of a study conducted by Rolf Brekken, University of ...

Affitech Gains Exclusive Worldwide Rights to Develop and Commercialize New Anti-VEGF Antibodies

24-Jul-2009 - Peregrine Pharmaceuticals, Inc. and Affitech A/S announced that they have entered into a licensing agreement for antibody therapeutic rights under Peregrine's preclinical anti-VEGF (Vascular Endothelial Growth Factor) antibody program. Under the terms of the agreement, Affitech will license ...

Affitech signs antibody research and licensing agreement with Roche

09-May-2007 - Affitech AS announced that they have signed a research and licensing agreement with Roche to produce fully human monoclonal antibodies against an unnamed oncology target. The agreement tasks Affitech with first using their proprietary phagemid library, high throughput screening technology and ...

Pharmexa and Affitech enter into an exclusive license agreement to promote Diabody technology

04-Apr-2007 - Pharmexa and Affitech A/S have entered into a license agreement to promote a single chain bi-specific antibody (diabody) technology to third parties for further product development, as well as to utilize the technology for Affitech's own research. Pharmexa has granted a worldwide exclusive ...

Affitech signs license agreement for single-chain antibody technology with Micromet

30-Mar-2007 - Affitech AS announced that it has signed an agreement with Micromet AG for a non-exclusive worldwide sub-licensable research license to the joint patent estate of Micromet and Enzon Pharmaceuticals, Inc. in the field of single-chain antibodies (SCA). Under the terms of the agreement, Affitech ...

Affitech renews exclusive worldwide phage display license from DKFZ

"Breitling" patents hold key position in human antibody discovery field

11-Apr-2006 - Affitech AS, announced that they have renewed an exclusive worldwide licensing agreement with DKFZ (German Cancer Research Center) of Heidelberg, Germany for the antibody library display patents, otherwise known as "Breitling" IP family. These patents cover the use of full-length pIII phage ...

Affitech and XOMA Sign Antibody Collaboration and Cross-License Agreement

01-Dec-2005 - Affitech AS and XOMA Ltd. announced that they have signed an antibody collaboration and crosslicense agreement for antibody-related technologies. Financial terms were not disclosed. Under the agreement, Affitech receives a license to use XOMA's bacterial cell expression (BCE) technology for ...